LIVIVO - Search results -

Search results

Result 1 - 10 of total 43

Search options

Article: PARP inhibitors in metastatic prostate cancer.

Taylor, Amy K / Kosoff, David / Emamekhoo, Hamid / Lang, Joshua M / Kyriakopoulos, Christos E

2023 Volume 13, Page(s) 1159557

Abstract: Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the treatment of prostate cancer. Their primary mechanism of action ... ...

Abstract	Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the treatment of prostate cancer. Their primary mechanism of action is
Language	English
Publishing date	2023-04-24
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1159557
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Are liquid biopsies ready for primetime?

Emamekhoo, Hamid / Lang, Joshua M

Cancer

2018 Volume 125, Issue 6, Page(s) 834–837

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Circulating Tumor DNA/genetics ; Exosomes/genetics ; Exosomes/metabolism ; Female ; Humans ; Liquid Biopsy/trends ; Male ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplastic Cells, Circulating/metabolism ; Neoplastic Cells, Circulating/pathology ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Biomarkers, Tumor ; Circulating Tumor DNA
Language	English
Publishing date	2018-12-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.31644
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Providing cessation treatment to every oncology patient who smokes: An essential component of cancer care.

Fiore, Michael C / Baker, Timothy B / Nolan, Margaret B / Emamekhoo, Hamid

Cancer

2021 Volume 128, Issue 6, Page(s) 1162–1164

MeSH term(s)	Humans ; Medical Oncology ; Neoplasms/therapy ; Smoking
Language	English
Publishing date	2021-12-07
Publishing country	United States
Document type	Editorial ; Research Support, N.I.H., Extramural ; Comment
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.34052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Patterns of Health Portal Use by Regular Portal Users Among Patients With Cancer: Results From the UWCCC Survivorship Program.

Emamekhoo, Hamid / Chandereng, Thevaa / Sesto, Mary E / Luoh, Rebecca / Bergeson, Elena M / Barbosa Carroll, Cibele / Tevaarwerk, Amye J

JCO clinical cancer informatics

2023 Volume 7, Page(s) e2200119

Abstract: Purpose: We sought to evaluate the patterns of portal usage among patients with cancer who regularly log in to the portal. These data will inform approaches to facilitate portal use among patients with cancer.: Patients and methods: We conducted a ... ...

Abstract	Purpose: We sought to evaluate the patterns of portal usage among patients with cancer who regularly log in to the portal. These data will inform approaches to facilitate portal use among patients with cancer. Patients and methods: We conducted a retrospective analysis of patient portal usage by patients with cancer at the University of Wisconsin Carbone Cancer Center. Our analysis focuses on patterns of portal use by regular users (≥ 2 portal logins/year, > 3 months) receiving ongoing oncology care between January 1, 2017, and December 31, 2019. Demographics, cancer characteristics, number of oncology visits per month, and portal usage data were extracted. Regular portal users were grouped and compared on the basis of their frequency of use. A linear mixed-effects model was used to determine if the frequency of oncology visits influenced the number of logins. Results: We identified 2076 regular portal users. The median number of portal logins/year was 72 for the entire cohort. Age and race were associated with frequency of portal logins. There was no difference in frequency of portal login on the basis of cancer type or stage. Each additional oncology office visit in a month increased the frequency of portal logins by 3.05 ± 0.11 (SE) within the same month. Messages and test result functionalities were used by 98.7% and 98.9% of the regular users, respectively. Regular users who logged in to portal more frequently used all five studied portal functionalities. Conclusion: Patients with cancer who use portals regularly use it more in proximity to an oncology office visit and use multiple available portal functionalities. These findings can direct strategic planning to facilitate portal utilization among those not engaged with this tool.
MeSH term(s)	Humans ; Retrospective Studies ; Survivorship ; Patients ; Patient Portals ; Patient Participation/methods ; Neoplasms/epidemiology ; Neoplasms/therapy
Language	English
Publishing date	2023-01-13
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ISSN	2473-4276
ISSN (online)	2473-4276
DOI	10.1200/CCI.22.00119
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.

McNeel, Douglas G / Emamekhoo, Hamid / Eickhoff, Jens C / Kyriakopoulos, Christos E / Wargowski, Ellen / Tonelli, Tommaso P / Johnson, Laura E / Liu, Glenn

Journal for immunotherapy of cancer

2023 Volume 11, Issue 12

Abstract: Purpose: We have previously reported that a plasmid DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) had greater clinical activity when given in combination with pembrolizumab to patients with metastatic, castration-resistant prostate cancer. ... ...

Abstract	Purpose: We have previously reported that a plasmid DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) had greater clinical activity when given in combination with pembrolizumab to patients with metastatic, castration-resistant prostate cancer. The current trial was conducted to evaluate vaccination with PD-1 blockade, using nivolumab, in patients with early, recurrent (M0) prostate cancer. Methods: Patients with M0 prostate cancer were treated with pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks for 3 months, and then every 4 weeks for 1 year of total treatment. Patients were then followed for an additional year off treatment. The primary objectives were safety and complete prostate-specific antigen (PSA) response (PSA<0.2 ng/mL). Results: 19 patients were enrolled. No patients met the primary endpoint of complete PSA response; however, 4/19 (21%) patients had a PSA decline >50%. Median PSA doubling times were 5.9 months pretreatment, 25.6 months on-treatment (p=0.001), and 9.0 months in the subsequent year off-treatment. The overall median radiographic progression-free survival was not reached. Grade 3 or 4 events included adrenal insufficiency, fatigue, lymphopenia, and increased amylase/lipase. 9/19 (47%) patients developed immune-related adverse effects (irAE). The development of irAE and increased CXCL9 were associated with increased PSA doubling time. Quantitative NaF PET/CT imaging showed the resolution of subclinical lesions along with the development of new lesions at each time point. Conclusions: In this population, combining nivolumab with pTVG-HP vaccination was safe, and immunologically active, prolonged the time to disease progression, but did not eradicate disease. Quantitative imaging suggested that additional treatments targeting mechanisms of resistance may be required to eliminate tumors. Trial registration number: NCT03600350.
MeSH term(s)	Male ; Humans ; Prostate-Specific Antigen ; Vaccines, DNA/therapeutic use ; Nivolumab/therapeutic use ; Positron Emission Tomography Computed Tomography ; Prostatic Neoplasms/pathology ; Castration
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77) ; Vaccines, DNA ; Nivolumab (31YO63LBSN)
Language	English
Publishing date	2023-12-14
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2023-008067
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.

Pozorski, Vincent / Park, Yeonhee / Mohamoud, Yusuf / Tesfamichael, Dahlia / Emamekhoo, Hamid / Birbrair, Alexander / Albertini, Mark R / Ma, Vincent T

Pigment cell & melanoma research

2023 Volume 36, Issue 6, Page(s) 501–511

Abstract: Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated with immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil ratios (NER) as a predictive ... ...

Abstract	Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated with immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil ratios (NER) as a predictive indicator in this population. In this retrospective study evaluating anti-PD-1 treated patients with advanced melanoma, progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and risk of high-grade (grade ≥3) immune-related adverse events (irAEs) were compared between groups defined by median pretreatment NLR and NER as well as median NLR and NER at 1-month post-treatment. Lower baseline NLR and NER were associated with improved OS [HR: 0.504, 95% CI: 0.328-0.773, p = .002 and HR: 0.442, 95% CI: 0.288-0.681, p < .001, respectively] on univariate testing. After accounting for multiple covariates, our multivariate analysis found that lower pretreatment NER was associated with better ORR (by irRECIST) (OR: 2.199, 95% CI: 1.071-4.582, p = .033) and improved OS (HR: 0.480, 95% CI: 0.296-0.777, p = .003). Baseline NLR, 1-month NLR, and 1-month NER were not associated with ORR, PFS, or OS outcomes; but 1-month NER correlated with lower risk of grade ≥3 irAEs (OR: 0.392, 95% CI: 0.165-0.895, p = .029). Our findings suggest baseline NER merits additional investigation as a novel prognostic marker for advanced melanoma patients receiving anti-PD-1-based regimens.
MeSH term(s)	Humans ; Neutrophils ; Eosinophils ; Retrospective Studies ; Treatment Outcome ; Melanoma ; Biomarkers
Chemical Substances	Biomarkers
Language	English
Publishing date	2023-07-07
Publishing country	England
Document type	Journal Article
ZDB-ID	2409570-9
ISSN	1755-148X ; 1600-0749 ; 0893-5785 ; 1755-1471
ISSN (online)	1755-148X ; 1600-0749
ISSN	0893-5785 ; 1755-1471
DOI	10.1111/pcmr.13109
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2444: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Image intensity histograms as imaging biomarkers: application to immune-related colitis.

Huff, Daniel T / Ferjancic, Peter / Namías, Mauro / Emamekhoo, Hamid / Perlman, Scott B / Jeraj, Robert

Biomedical physics & engineering express

2021 Volume 7, Issue 6

Abstract: Purpose. ...

Abstract	Purpose.
MeSH term(s)	Biomarkers ; Colitis/diagnosis ; Fluorodeoxyglucose F18 ; Humans ; Positron Emission Tomography Computed Tomography ; Retrospective Studies
Chemical Substances	Biomarkers ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
Language	English
Publishing date	2021-09-30
Publishing country	England
Document type	Journal Article
ISSN	2057-1976
ISSN (online)	2057-1976
DOI	10.1088/2057-1976/ac27c3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A case of metastatic renal cell carcinoma with concomitant Castleman's disease treated with immunotherapy.

Lozar, Taja / Brunner, Matthew J / Shah, Sujal I / Kyriakopoulos, Christos E / Emamekhoo, Hamid

Urology case reports

2021 Volume 38, Page(s) 101720

Abstract: Castleman's disease (CD) is an uncommon lymphoproliferative process that can present concurrent to other solid organ malignancy, especially in selected populations. Concomitant CD and renal cell carcinoma (RCC) are challenging in terms of diagnosis and ... ...

Abstract	Castleman's disease (CD) is an uncommon lymphoproliferative process that can present concurrent to other solid organ malignancy, especially in selected populations. Concomitant CD and renal cell carcinoma (RCC) are challenging in terms of diagnosis and treatment. Assessment of CD involvement is a crucial step in selecting the optimal treatment strategy. Here we report a case of metastatic RCC and concurrent CD treated with surgery and immunotherapy.
Language	English
Publishing date	2021-05-17
Publishing country	United States
Document type	Case Reports
ZDB-ID	2745459-9
ISSN	2214-4420
ISSN	2214-4420
DOI	10.1016/j.eucr.2021.101720
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data.

Emamekhoo, Hamid / Carroll, Cibele B / Stietz, Chelsea / Pier, Jeffrey B / Lavitschke, Michael D / Mulkerin, Daniel / Sesto, Mary E / Tevaarwerk, Amye J

JCO clinical cancer informatics

2022 Volume 6, Page(s) e2200020

Abstract: Purpose: Structured data elements within electronic health records are health-related information that can be entered, stored, and extracted in an organized manner at later time points. Tracking outcomes for cancer survivors is also enabled by ... ...

Abstract	Purpose: Structured data elements within electronic health records are health-related information that can be entered, stored, and extracted in an organized manner at later time points. Tracking outcomes for cancer survivors is also enabled by structured data. We sought to increase structured data capture within oncology practices at multiple sites sharing the same electronic health records. Methods: Applying engineering approaches and the Plan-Do-Study-Act cycle, we launched dual quality improvement initiatives to ensure that a malignant diagnosis and stage were captured as structured data. Intervention: Close Visit Validation (CVV) requires providers to satisfy certain criteria before closing ambulatory encounters. CVV may be used to track open clinical encounters and chart delinquencies to encourage optimal clinical workflows. We added two cancer-specific required criteria at the time of closing encounters in oncology clinics: (1) the presence of at least one malignant diagnosis on the Problem List and (2) staging all the malignant diagnoses on the Problem List when appropriate. Results: Six months before the CVV implementation, the percentage of encounters with a malignant diagnosis on the Problem List at the time of the encounter was 65%, whereas the percentage of encounters with a staged diagnosis was 32%. Three months after cancer-specific CVV implementation, the percentages were 85% and 75%, respectively. Rates had increased to 90% and 88% more than 2 years after implementation. Conclusion: Oncologist performance improved after the implementation of cancer-specific CVV criteria, with persistently high percentages of relevant malignant diagnoses and cancer stage structured data capture 2 years after the intervention.
MeSH term(s)	Humans ; Neoplasm Staging ; Neoplasms/diagnosis ; Neoplasms/therapy ; Survivorship ; Universities ; Wisconsin
Language	English
Publishing date	2022-07-08
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ISSN	2473-4276
ISSN (online)	2473-4276
DOI	10.1200/CCI.22.00020
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.

Zarling, Lucas / Emamekhoo, Hamid / Bhutani, Gauri / Ziemlewicz, Timothy / Matkowskyj, Kristina A / Kyriakopoulos, Christos E

Anticancer research

2020 Volume 40, Issue 3, Page(s) 1527–1534

Abstract: We report a case of rapid evolution of polycystic liver disease in a 76-year-old patient with metastatic renal cell carcinoma who underwent treatment with numerous antineoplastic agents. The aim was to identify a causative etiology for these hepatic ... ...

Abstract	We report a case of rapid evolution of polycystic liver disease in a 76-year-old patient with metastatic renal cell carcinoma who underwent treatment with numerous antineoplastic agents. The aim was to identify a causative etiology for these hepatic cysts of unclear origin. The cystic lesions of the patient were ultimately innumerable and developed rapidly, more than tripling the total liver volume from complete absence over the course of 24 months. The hepatic lesions continued to grow despite an otherwise moderate tumor response. Prior to patient death, the patient remained relatively asymptomatic from the cyst burden and was without signs of grossly metastatic disease. This rapid development of polycystic liver disease most likely represents a previously unseen medication side-effect of cabozantinib or pazopanib. It is important to identify adverse effects of novel antineoplastic agents in this time of oncological medical discovery.
MeSH term(s)	Aged ; Anilides/administration & dosage ; Anilides/adverse effects ; Carcinoma, Renal Cell/complications ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Cysts/chemically induced ; Cysts/complications ; Cysts/etiology ; Cysts/pathology ; Humans ; Kidney Neoplasms/complications ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Liver Diseases/complications ; Liver Diseases/etiology ; Liver Diseases/pathology ; Male ; Neoplasm Metastasis ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects
Chemical Substances	Anilides ; Pyridines ; Pyrimidines ; Sulfonamides ; cabozantinib (1C39JW444G) ; pazopanib (7RN5DR86CK)
Language	English
Publishing date	2020-03-05
Publishing country	Greece
Document type	Case Reports ; Journal Article
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.14098
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito